The collaboration will allow the partners to globally expand financial advisory services and cross-border transactions for life sciences and biopharmaceutical client companies
BOSTON & SHANGHAI - Outcome Capital, announced that the companies have entered into a global strategic partnership, allowing both to globally expand their respective investment banking practices for providing strategic and financial advisory services, committed to the life sciences and healthcare sectors.
Outcome Capital specializes in serving the US and EU regions, offering advisory and investment banking services primarily to life sciences and healthcare companies. Their expertise is geared towards aiding management teams and board members in navigating the financial and strategic aspects of their businesses.
On the other hand, YAFO Capital focuses on the Chinese and broader Asian markets. This Shanghai-based investment and advisory firm provides services such as clinical strategy development, asset transaction support, and licensing services to biopharmaceutical companies worldwide. Their specialization lies in offering guidance and solutions tailored to the unique dynamics of these markets.
“Outcome Capital continues to develop innovative approaches to life sciences partnerships and mergers & acquisitions in an effort to offer our clients multiple paths to success. China’s increasing role in the global biotechnology sector provides rich opportunities for Sino-U.S. cooperation,” said Dr. Oded Ben-Joseph, Managing Partner at Outcome Capital.
“We are delighted to announce our partnership with Outcome. Together, we are uniquely positioned to help global clients unlock the full potential of their innovative pipelines to Asian markets and globally,” commented Sean Jiang, Founder & CEO of YAFO Capital, and Kun Tao, Head of U.S. business at YAFO Capital.
This fresh collaboration will expand the geographic reach of both companies and facilitate cross-border transactions with increased overall capacity. As a result, client organizations will gain enhanced opportunities for value generation and substantial business development outcomes on a global level.
“This agreement enables us to focus on our core markets in the U.S. and Western Europe, while leveraging the investment banking and life sciences strength of YAFO in China and across Asia,” commented Arnold Freedman, Managing Partner at Outcome Capital.
“At YAFO, we understand the immense value that Chinese biotech companies bring to the global life sciences landscape. Our strategic partnership with Outcome further strengthens our commitment to support client ambitions by providing access to a vast network of potential global licensing partners and extensive industry insights,” added Victor Ye, Managing Partner and Head of China Division at YAFO Capital.
